These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18158039)

  • 21. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
    Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC
    J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.
    Sim HG; Telesca D; Culp SH; Ellis WJ; Lange PH; True LD; Lin DW
    J Urol; 2008 May; 179(5):1775-9. PubMed ID: 18343432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
    J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer volume at biopsy predicts clinically significant upgrading.
    Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
    J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
    Meeks JJ; Thaxton CS; Loeb S; Roehl KA; Helfand BT; Catalona WJ
    J Urol; 2008 Apr; 179(4):1340-3. PubMed ID: 18289590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management.
    Nguyen PL; Chen MH; Catalona WJ; Alexander BM; Roehl KA; Loeb S; D'Amico AV
    Cancer; 2008 Dec; 113(11):3146-52. PubMed ID: 18932254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?
    Caire AA; Sun L; Ode O; Stackhouse DA; Maloney K; Donatucci C; Mouraviev V; Polascik TJ; Robertson CN; Albala DM; Moul JW
    Urology; 2009 Sep; 74(3):643-7. PubMed ID: 19501891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
    Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
    Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
    Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
    Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive significance of surgical margin status after prostatectomy for prostate cancer during PSA era.
    Mann MJ; DeCastro GJ; Desai M; Benson MC; McKiernan JM
    Urology; 2008 Dec; 72(6):1203-7. PubMed ID: 18674807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL.
    Pelzer AE; Colleselli D; Bektic J; Schaefer G; Ongarello S; Schwentner C; Aigner F; Mitterberger M; Steiner E; Bartsch G; Horninger W
    BJU Int; 2008 May; 101(10):1223-6. PubMed ID: 18190631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
    Thomas C; Wiesner C; Melchior S; Gillitzer R; Schmidt F; Thüroff JW
    J Urol; 2008 Nov; 180(5):1938-41; discussion 1941. PubMed ID: 18801501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of treatment regret in low-income, uninsured men with prostate cancer.
    Hu JC; Kwan L; Krupski TL; Anger JT; Maliski SL; Connor S; Litwin MS
    Urology; 2008 Dec; 72(6):1274-9. PubMed ID: 18313115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database.
    White WM; Sadetsky N; Waters WB; Carroll PR; Litwin MS
    J Urol; 2008 Dec; 180(6):2409-13; discussion 2414. PubMed ID: 18930270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.